Mountain West AIDS Education and Training Center



HIV/STD Update

YKHC 6/2019 Terri Bramel, PA-C (907) 729-2907 Claire Lewis, ANP

tlbramel@anthc.org Claire_Lewis@YKHC.org



I Have no conflicts of interest to disclose






Topics

- STD update
- PrEP- pre-exposure prophylaxis
- Testing and treatment as prevention
- Screening for HIV

Syphilis in Alaska 2008 - 2018



Demographics

- About 80% of 2018 cases are in Anchorage; 90% in males; Age range is 20 – 63
- About 80% are MSM (CDC notes that MSM accounted for majority of reported syphilis in 2016)
- Out of all confirmed cases, about 25% are co-infected with HIV

Syphilis-Demographics shifting, 2019 to date

- Preliminary data for 2019, on pace with first quarter 2018
- Moving into heterosexual, IDU, homeless
- 50% with associated drug use
- 34% in AIAN
- In April increase in meth users and women

Syphilis Screening Recommendations

Pregnant Women	MSM	Persons Living with HIV
 All pregnant women at 1st prenatal visit 	If sexually active:	If sexually active:
 Retest early in the 3rd 	 At least annually 	 At first HIV evaluation
 trimester At delivery if at ↑ risk 	• Every 3-6 mos if at ↑ risk	 At least annually thereafter
		• Every 3-6 mos if at ↑ risk

Promptly report positive syphilis screens

Promptly treat confirmed sexual contacts while awaiting diagnostic test results.

Promptly treat and report all suspected and confirmed cases of syphilis. SOE staff happy to help with staging, consultation and partner management

(907) 269-8000


Preventive Treatment of Syphilis

 All persons who report exposure to syphilis should be prophylactically treated at the time of testing, do not wait for test results. Remember the incubation period for syphilis is as long as 90 days.

– During that time:



Gonorrhea Case Rates – Alaska and US, 2008-2017



Alaska Gonorrhea 2018

- 489 confirmed cases at ASPHL
 - 46% involved extragenital site
 - 40% of those had negative urine tests



- Disproportionately impacting teens, young adults and ethnic minorities
- Nationally 30% of infections resistant to at least one drug, thus 2 drug treatment advised.
- 2019 rates comparable to 2018, 2019 YTD: hetero > MSM

Extragenital Screening for CT/GC

- Testing at all anatomical sites used for sexual activity
- Requires a complete sexual history to elicit information, offer it regardless
- High rates of under-diagnosis of STD among gay, bi-sexual and other MSM Urine-only screening misses 53% of CT & 64% of GC in MSM
- Oral/rectal swab is off-label use of the Aptima DNA probe


Unisex blue handled swab Validated at State lab, ANMC, commercial labs

Self Collection has high acceptability and much higher uptake. Patients are pretty good at it & they prefer it



UW STD PTC/Madison Clinic Self-Testing Program







Email aradford@uw.edu for free posters for your clinic/facility

NOW AVAILABLE IN SPANISH


Self-Collection of Rectal Swab ATTENTION: Read ALL instructions before you begin!



Chlamydia Case Rates – Alaska and US, 2000-2018



Chlamydia Case Rates – Alaska and US, 2015-2018



STD's predict future HIV Risk among MSM

Rectal GC or CT




1 in 15 MSM were diagnosed with HIV within 1 year.*

Primary or Secondary Syphilis



1 in 18 MSM were diagnosed with HIV within 1 year.**

No rectal STD or syphilis infection




1 in 53 MSM were diagnosed with HIV within 1 year.*

HIV

- No big changes in Alaska numbers in 2018
 - 22 new dx / 54 % AIAN
 - Increase % in heterosexual, PWID
- Recent years 45-54% new HIV diagnoses in AIAN

Al/AN have increasing rates of new infection





Other Factors

- Multiple partners
- Time spent in correctional facilities
- Increased use of drug and <u>alcohol</u>
- Use of internet networks to find partners social networking

Source: Alaska HIV/STD Program staff (and friends)

HIV Screening Recommendation

EVERYONE!

- Re-Screen at least annually patients with:
 - Known risk factors (MSM, IDU, HRH)
 - Multiple sexual partners
 - History of substance abuse
 - History of mental illness
 - Diagnosis of HCV, STD, or history of recurrent STD
 - Patients who report sex with travel





ENDING THE HIV EPIDEMIC:A PLAN FOR AMERICA



www.hiv.gov














Ending the HIV Epidemic: A Plan for America

Reduce new HIV infections by 75% in the next 5 years and 90% in the next 10 years

- Diagnose all people with HIV as early as possible after infection
- Treat the infection rapidly and effectively to achieve sustained viral suppression
- Protect people at risk for HIV using potent and proven prevention interventions, including PrEP (Pre-exposure prophylaxis), a medication that can prevent HIV infections

PLWHIV not in care pass most of new infections



HIV TRANSMISSIONS IN 2016		
% OF PEOPLE WITH HIV	STATUS OF CARE	ACCOUNTED FOR X% OF NEW TRANSMISSIONS*
15%	didn't know they had HIV	38%
23%	knew they had HIV but weren't in care	43%
11%	in care but not virally suppressed	20%
51 %	taking HIV medicine and virally suppressed	0%

^{*}Values do not equal 100% because of rounding

SOURCE: Vital Signs, 2019

Diagnose HIV as early as possible Treat HIV quickly and effectively Treat HIV quickly at risk Protect people at risk Respond quickly to clusters of new cases

bit.ly/2DW9Deb






What is PrEP?

- A prevention strategy in which a high-risk individual takes a medication regularly (along with continued behavioral risk-reduction strategies) to prevent HIV infection
- Tenofovir-emtricitabine (Truvada) approved for HIV PrEP by the FDA in July 2012
- Added benefits: some protection against HSV and HBV




www.nytimes.com

Sexual PrEP for HIV Prevention Estimated Protection in Adherent Patients



iPrEx OLE confirmed prior estimates



Who to consider for PrEP

- Individuals with "substantial risk" for HIV
- Examples:
 - Man or woman in relationship with an HIV-positive partner (not virally suppressed)
 - Gay or bisexual man not in a mutually monogamous relationship & not using condoms 100%
 - Man or woman with recent STI
 - Man or woman sexually active with high-risk individuals
 - Man or woman who uses injection drugs
 - Commercial sex workers
 - Serodiscordant couple who want to conceive
 - Anyone who asks...

PrEP Guidelines:

A. Determine Eligibility

- Substantial ongoing risk for HIV
- Able to take a pill every day and return every 3 months
- Screen for HIV and consider need for HIV RNA (viral load)
- Check hepatitis B antibody panel and renal function

B. Prescribe PrEP

- Truvada 1 tab PO daily
- No more than 90 days at a time
- Emphasize importance of adherence

PrEP Guidelines:

C. Continue Counseling


- Continue risk-reduction counseling and other preventive measures (condoms, clean needles, etc)
- Remember PrEP is not a stand-alone strategy

D. Lab Monitoring

- Every 3 month HIV test
- Every 3-6 month STI screening
- Renal function at 3 months, then every 3-6 months

How long before I'm protected?

Time to Maximum Intracellular Concentration of Tenofovir Diphosphate (TFV-DP)



PrEP efficacy and future directions



Number needed to treat (NNT) to prevent one case of HIV: 13-60.1

An estimated **33%** of HIV infections in MSM would be prevented over 10 years with 40% uptake and 60% adherent.²

One thing that is needed around the world = prevention **options**.



CDC FACT SHEET

PrEP: A New Tool for HIV Prevention

Pre-exposure prophylaxis, or PrEP, is a new HIV prevention method in which people who do not have HIV infection take a pill daily to reduce their risk of becoming infected. The pill contains medicines that prevent HIV from making new virus as it enters

CDC Interim Guidance on HIV Pre-Exposure Prophylaxis

Before initiating PrEP

Determine eligibility:

- Document negative HIV antibody test immediately before starting PrEP medication.
- Test for acute HIV infection if patient has symptoms consistent with acute HIV infection or reports unprotected sex with an HIV-positive person in the preceding month.
- Determine if women are planning to become pregnant, are currently pregnant, or are breastfeeding.
- Confirm that patient is at ongoing, very high risk for acquiring HIV infection.
- If any sexual partner is known to be

Beginning PrEP medication regimen:


- Prescribe tenofovir disoproxil fumarate 300 mg (TDF) plus emtricitabine 200 mg (FTC) (i.e., one Truvada [Gilead Sciences] tablet) daily.
- In general, prescribe no more than a 90-day supply, renewable only after HIV testing confirms that patient remains HIV-uninfected. For women, ensure that pregnancy test is negative or, if pregnant, that the patient has been informed about use during pregnancy.
- If active hepatitis B infection is diagnosed, consider using TDF/FTC, which may serve as both

- Every 2–3 months, assess risk behaviors and provide riskreduction counseling and condoms. Assess STI symptoms and, if present, test and treat for STIs as needed.
- Every 6 months, test for bacterial STIs even if asymptomatic, and treat as needed.
- Three months after initiation, then every six months while on PrEP medication, check serum creatinine and calculate creatinine clearance.

On discontinuing PrEP (at patient request, for safety concerns, or if HIV infection



Effect of HIV Prevention Strategies from Randomized Clinical Trials



Abdool Karim, SS et al Lancet 2011: Jul 17

What prevents PrEP from being adopted?

- Awareness/Education
 - Provider
 - Patients
- Resistance to departure from condom-centric prevention counseling
- Integration into primary care and STI treatment settings
- Cost

PreP is One Piece of the HIV Prevention Puzzle





Harness your husky.

Evidence for Condoms



- condoms not FDA approved for anal sex (off label Rx)
- One large 2yr study in 2915 MSM showed a
 76% HIV risk reduction with 100% use
- Retrospective study by Dawn Smith at the CDC in 2013, found always condom use stopped 7 of 10 anal transmissions

70% less than "sometimes used" 68% less than "never used"

- Only 16.4% (1 in 6) MSM reported 100% use throughout the study period
- Still Recommended! Condoms don't *have* to be perfect

70% risk reduction of already small HIV risk (1.38% per receptive anal sexual act) = 0.4%!

Smith D et al. Condom efficacy by consistency of use among MSM: US. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, abstract 32, 2013. Detels R et al. Seroconversion, sexual activity, and condom use among 2915 HIV seronegative men followed for up to 2 years. J AIDS 2:77-83, 1989.



Retrospective analysis of

- VAX004 (n=3102
 MSM, 4yr f/u), first
 HIV vaccine trial,
 1998-1999
- EXPLORE (n=4264 MSM, 3yr f/u), largest behavioral HIV study, 1999-2001

Information, Inspiration and Advocacy for People with HIV/AIDS and Hepatitis C

HOME

ABOUT US INFORMATION

HELP LINES SUPPORT US





DONATE NOW

SEARCH

Search

SIGN UP E-NEWS / ALERTS

Email Address

GO

ARTICLES

Health care reform

HCV care & treatment

Hepatitis C policy

HIV care & treatment

HIV cure advocacy

HIV policy

HIV prevention

CONTRIBUTORS



PrEP (Pre-Exposure Prophylaxis)



Order any of our 3 educational booklets on PrEP.



Watch any of our educational videos on PrEP.



Email us a question you have about PrEP.



Find other websites and information about PrEP.

Getting PrEPped Flow Chart:

This health care tool can help consumers and navigators with working through the process for finding a clinician, getting a prescription and covering the costs of PrEP. It's laid out on a legal-sized sheet of paper, so feel free to print it on a desktop printer. In English and Spanish.

PrEP/PEP point-of-care awareness cards:

Order form: www.projectinform.org/prep-pep-cards/.

PrEP/PEP medication and patient assistance programs and copay programs:

Click on the links at the bottom of that page at the Fair Pricing Coalition.

DIRECTORIES FOR Prep-FRIENDLY PROVIDERS:

PleasePrEPMe Provider Directory Greater Than AIDS Provider Directory

TWITTER FEED




Project Inform

- Prevention Summary
- Condoms: 70% risk reduction for anal sex if 100% of the time
- estimate only 1:6 MSM using condoms 100%
- TasP: undetectable viral load, transmission approaches 0%

2018 YKHC STI+ Rates





2018 YKHC STI+ Rates

	Village Tx	Bethel Tx	СТ	GC	CT/GC	Total: 854
January	38	33	60	7	7	74
February	40	32	66	5	4	75
March	40	31	59	9	4	72
April	55	27	69	12	7	87
May	56	36	74	19	1	94
June	13	22	32	5	0	37
July	26	24	47	5	1	53
August	58	30	84	2	3	89
September	27	19	45	3	0	48
October	61	25	90	0	0	90
November	36	22	54	4	0	58
December	35	38	61	1	5	77

Syphilis in the Last Frontier Webinar from State Epi

YouTube Link:

https://youtu.be/JQpwpZQdDjU



STI + results in YKHC Region

2017


• 814 + cases

2018

• 853 + cases

2019: January – May


• 356 + cases so far



HIV in YKHC Region

Spring 2016 – Spring 2019

11 new cases of HIV diagnosed



We ALL have responsibility to deal with STI testing and treatment

 Due to State of Alaska decrease in Public Health Nursing personnel



Goal is to end HIV Epidemic

Identify those who need PrEP and initiate

If/when they request PrEP (labs can be pending)



U=U

Having a Undetectable Viral Load

- Means cannot pass along the HIV virus to a partner
- Helps decrease STIGMA of having HIV virus




If we don't ask..

A person will not tell...

But HOW we ask, makes a difference in doing a comprehensive Sexual History







Course >



Question
Bank





Tools & Calculators >



Master Bibliography

Q

National HIV Curriculum

A free educational web site from the University of Washington and the AETC National Coordinating Resource Center.



Funded by a grant from the Health Resources and Services Administration

Course Modules

Screening and Diagnosis

This module is for any health care provider who would like to establish core competence in testing for HIV, recognizing acute HIV infection, and linking persons diagnosed with HIV to medical care.

Overview / Quick Reference >

Rapidly access info about Screening and Diagnosis

Self-Study CNE/CME

Track your progress and receive CE credit

Question Bank CNE/CME

Interactive board-review style questions with CE credit

Clinical Challenges COMING SOOM

Expert opinions for challenging and controversial cases

Basic HIV Primary Care

The Basic HIV Primary Care module is intended for any clinician who may interact with persons who have HIV infection in a clinical setting, with an emphasis on the primary care management issues related HIV.

Overview / Quick Reference >

Rapidly access info about Basic HIV Primary Care

Self-Study CNE/CME

Track your progress and receive CE credit

Question Bank CNE/CME


Interactive board-review style questions with CE credit

Clinical Challenges COMING SOOM

Expert opinions for challenging and controversial cases



Short free video updates on these topics...





Questions?





Email: tlbramel@anthc.org Claire_Lewis@ykhc.org

